OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

Core Viewpoint - OSE Immunotherapeutics reports a significant decrease in cash position as of June 30, 2025, and anticipates funding operations until Q4 2026, while exploring options to extend its financial runway [4][5][6]. Financial Position - As of June 30, 2025, OSE Immunotherapeutics' cash position totaled €41.6 million, down from €64.2 million as of December 31, 2024 [4]. - The cash position includes €25.4 million in cash and cash equivalents, and €16.2 million in fixed-term deposits classified as current and non-current financial assets [4]. Funding Outlook - The company believes its operations are funded until the beginning of Q4 2026, factoring in the potential exercise of remaining warrants issued to Vester Finance, but excluding any upcoming milestone payments from current partnerships [5]. - If anticipated milestones are received in 2026, the cash runway could extend to at least Q1 2027 [5]. Strategic Initiatives - To extend its financial runway beyond 2026, the company is evaluating several options, including potential new strategic partnerships, equity financing, restructuring existing debt, and possible milestone payments from current partnerships [6]. Partnership Update - The company has updated its expectations regarding the AbbVie partnership related to ABBV-230, indicating a delay in the initiation of the Phase 1 trial and the associated milestone payment [3].